Why the study?
Thromboembolic events remain a leading cause of maternal morbidity and mortality and are not decreasing, necessitating review of anticoagulant protocols and new clinical guidelines.
Low molecular weight heparins remain the preferred anticoagulant for preventing and treating venous thromboembolism in obstetric patients.
Persistent VTE burden in pregnancy demands ongoing vigilance; this review leaves open refined prophylaxis strategies amid rising risk factors.
Thromboembolic events in pregnant women, women in labor and puerperal traditionally take one of the leader places in maternal morbidity and mortality structure and do not tend to decrease. The successes in extragenital pathology treatment, transplantology, reproductive technologies, effective treatment of infertility as well as older pregnant women number increasing contribute it much. The analytical review of published russian and foreign trials and regulatory papers concerning the definition for treatment and thrombophilic and thrombotic conditions using various groups of anticoagulants was presented. The authors focus on novelty and points that distinguish new clinical guidelines from the previous one as well as on possibility to adopt them to the real clinical practice and position that does not coincide with the foreign investigator’s opinion. Low molecular weight heparins,) are the drugs of choice to prevent and treatment of venous thromboembolic complications in pregnant women and puerperal.
No takes yet. Share an insight, caveat, or question.
Габитова et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: